Moderna Inc.
Moderna Reports Fourth Quarter 2025 Financial Results and Business Updates
Summary
Moderna, Inc. announced its financial results for the fourth quarter and full year 2025, reporting a fourth quarter revenue of $678 million and a full-year revenue of $1.9 billion. The company experienced a net loss of $(826) million for Q4 2025 and $(2.8) billion for the full year. Moderna highlighted its progress in mRNA vaccine development, including regulatory filings and clinical trial updates. The company also provided financial guidance for 2026, targeting up to 10% revenue growth. Moderna's cash position as of December 31, 2025, was $8.1 billion.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement